CSO & founder Wolfgang Sadee honored as a Highly Ranked Scholar by ScholarGPS in the 2025 Global Scholar Rankings 
Recognition Underscores Company's Commitment to Excellence in Novel Pain and Addiction Therapeutics

 

Austin, Texas- December 2025- Aether Therapeutics, a clinical-stage biopharmaceutical company developing safer therapeutics for pain and addiction, today announced that Dr. Wolfgang Sadee, CSO, has been honored as a Highly Ranked Scholar by ScholarGPS in the 2025 Global Scholar Rankings, placing them in the top 0.05% of scholars worldwide in personalized medicine and related disciplines.

 

This prestigious recognition reflects Dr Sadee's exceptional career trajectory, prolific publication record, and outstanding contributions to biomedical innovation—areas that directly align with Aether Therapeutics' mission to transform pain management and addiction treatment through precision therapeutics.

 

"We are proud to see Wolfgang Sadee's world-class expertise recognized on such a distinguished platform," said Aaron Schuchart, at Aether Therapeutics. "His leadership in opioid research and personalized medicine has been instrumental in advancing our scientific strategy and bringing breakthrough solutions to patients who desperately need safer alternatives."

 

ScholarGPS rankings are determined by artificial intelligence and data science analysis of over 200 million publications and 3 billion citations, evaluating scholars across 30 million researchers and 120,000 institutions globally. The Highly Ranked Scholar designation honors exceptional lifetime achievement and recent contributions across specific scientific and clinical disciplines.